The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Fri., Dec. 3, 6:05 PM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #67. Salix Pharmaceuticals, Ltd. Santarus, Inc.

Acquirer: Salix Pharmaceuticals, Ltd. (SLXP)
Acquiree: Santarus, Inc. (SNTS)
Details: Salix Pharmaceuticals, Ltd. and Santarus, Inc. announced that the companies have entered into a definitive merger agreement under which Salix will acquire all of the outstanding common stock of Santarus for $32.00 per share in cash (without interest). The all-cash transaction values Santarus at approximately $2.6 billion. The $32.00 per share price represents an approximately 36% premium over Santarus' November 6, 2013 closing price of $23.53 per share and an approximately 39% premium over Santarus' average closing stock price for the prior 30-trading day period. The proposed transaction has been unanimously approved by the Boards of Directors of Salix and Santarus. The companies expect to close the transaction in the first quarter of 2014.

Salix Pharmaceuticals is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. Co.'s products include among others, XIFAXAN550® (rifaximin) Tablets, indicated for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years and older; XIFAXAN (rifaximin) tablets, indicated for the treatment of patients 12 years of age and older with travelers' diarrhea; and APRISO® (mesalamine) extended-release capsules, indicated for the maintenance of remission of ulcerative colitis.

Open the SLXP Page at The Online Investor »

Salix Pharmaceuticals is a pharmaceutical company engaged in acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a range of gastrointestinal diseases, which are those affecting the digestive tract. Co.'s products include among others, XIFAXAN550® (rifaximin) Tablets, indicated for the reduction in risk of overt hepatic encephalopathy recurrence in patients 18 years and older; XIFAXAN (rifaximin) tablets, indicated for the treatment of patients 12 years of age and older with travelers' diarrhea; and APRISO® (mesalamine) extended-release capsules, indicated for the maintenance of remission of ulcerative colitis.

Open the SNTS Page at The Online Investor »

Company Name: 
Salix Pharmaceuticals Ltd
Website: 
www.salix.com
Sector: 
Drugs & Pharmaceuticals
Company Name: 
Santarus Inc
Website: 
www.santarus.com
Sector: 
Drugs & Pharmaceuticals
 

Quotes delayed 20 minutes

Email EnvelopeFree Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Drugs & Pharmaceuticals M&A - Slide 67 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2021, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.